{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:32Z","timestamp":1791310052144,"version":"4.3.1"},"publisher-location":"Chichester, UK","reference-count":70,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005088.pub3","type":"reference-entry","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T11:52:25Z","timestamp":1406116345000},"source":"Crossref","is-referenced-by-count":76,"title":["Bisphosphonate therapy for osteogenesis imperfecta"],"prefix":"10.1002","author":[{"given":"Kerry","family":"Dwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A","family":"Phillipi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Basel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8","key":"10.1002\/14651858.CD005088.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5-6","key":"10.1002\/14651858.CD005088.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpem-2012-0016","article-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta","volume":"25","author":"Barros","year":"2012","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomised controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9902","key":"10.1002\/14651858.CD005088.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta:a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"Dimeglio","year":"2005","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD005088.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1282-9","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9419","key":"10.1002\/14651858.CD005088.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"Journal of Pediatric Orthopaedics"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/adc.2007.125468","article-title":"Two doses of pamidronate in infants with osteogenesis imperfecta","volume":"93","author":"Senthilnathan","year":"2008","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD005088.pub3-BIB15|cit15","first-page":"S12","article-title":"Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]","volume":"20 Suppl","author":"Glorieux","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD005088.pub3-BIB17|cit17","unstructured":"Food Drug Administration (FDA) Center for Drug Evaluation and Research Statistical review and evaluation - clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI) http:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/developmentresources\/ucm072901.pdf"},{"key":"10.1002\/14651858.CD005088.pub3-BIB18|cit18","unstructured":"NCT00063479 Bisphosphonate treatment of osteogenesis imperfecta http:\/\/clinicaltrials.gov\/show\/NCT00063479"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","article-title":"Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis","volume":"129","author":"Antoniazzi","year":"1996","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi","year":"2010","journal-title":"European Journal of Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0003-9993(98)90207-6","article-title":"Effect of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta","volume":"79","author":"Gerber","year":"1998","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"216","key":"10.1002\/14651858.CD005088.pub3-BIB24|cit24","first-page":"228","article-title":"Phyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta","volume":"Jul-Aug","author":"Granda","year":"1977","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"10.1002\/14651858.CD005088.pub3-BIB25|cit25","unstructured":"NCT00131469 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI) http:\/\/clinicaltrials.gov\/show\/NCT00131469"},{"key":"10.1002\/14651858.CD005088.pub3-BIB26|cit26","series-title":"Proceedings of the 63rd Annual Meeting of the American Society of Human Genetics; 2013 Oct 22-26; Boston","first-page":"27","article-title":"Teriparatide, the first anabolic agent for treatment of osteogenesis imperfecta improves bone mineral density at the hip and spine: a randomized, blinded, placebo-controlled trial [abstract]","author":"Nagamani","year":"2013"},{"issue":"7","key":"10.1002\/14651858.CD005088.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD005088.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","article-title":"Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta","volume":"86","author":"Alanay","year":"2010","journal-title":"American Journal of Human Genetics"},{"issue":"26","key":"10.1002\/14651858.CD005088.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","article-title":"Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta","volume":"88","author":"Becker","year":"2011","journal-title":"American Journal of Human Genetics"},{"issue":"9041","key":"10.1002\/14651858.CD005088.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD005088.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jmg.28.7.433","article-title":"Osteogenesis imperfecta: translation of mutation to phenotype","volume":"28","author":"Byers","year":"1991","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD005088.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.me.43.020192.001413","article-title":"Osteogenesis imperfecta","volume":"43","author":"Byers","year":"1992","journal-title":"Annual Review of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00008480-200012000-00016","article-title":"Osteogenesis imperfecta: perspectives and opportunities","volume":"12","author":"Byers","year":"2000","journal-title":"Current Opinion in Pediatrics"},{"key":"10.1002\/14651858.CD005088.pub3-BIB35|cit35","unstructured":"Byers 2013 [pers comm] OI [personal communication] Email to: D Basel 2013"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta","volume":"39","author":"Cabral","year":"2007","journal-title":"Nature Genetics"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcified Tissue International"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","article-title":"Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review","volume":"51","author":"Castillo","year":"2009","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A Single Recurrent Mutation in the 5'-UTR of IFITM5 Causes Osteogenesis Imperfecta Type V","volume":"91","author":"Cho","year":"2012","journal-title":"American Journal of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD005088.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200208000-00003","article-title":"Advances in Osteogenesis Imperfecta","volume":"401","author":"Cole","year":"2002","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajmg.1320220205","article-title":"Lethal neonatal chondrodysplasias in the West of Scotland 1970-1983 with a description of a thanatophoric, dysplasialike, autosomal recessive disorder, Glasgow variant","volume":"22","author":"Connor","year":"1985","journal-title":"American Journal of Medical Genetics"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005088.pub3-BIB44|cit44","doi-asserted-by":"crossref","unstructured":"Erviti J Alonso A Oliva B Gorricho J L\u00f3pez A Timoner J Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study http:\/\/bmjopen.bmj.com\/content\/3\/1\/e002091","DOI":"10.1136\/bmjopen-2012-002091"},{"key":"10.1002\/14651858.CD005088.pub3-BIB45|cit45","unstructured":"Food Drug Administration (FDA) Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/UCM270958.pdf"},{"key":"10.1002\/14651858.CD005088.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [abstract]","volume":"96","author":"Fisher","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcified Tissue International"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"issue":"Suppl","key":"10.1002\/14651858.CD005088.pub3-BIB49|cit49","first-page":"1043","article-title":"Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]","volume":"20","author":"Glorieux","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7414","key":"10.1002\/14651858.CD005088.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005088.pub3-BIB51|cit51","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD005088.pub3-BIB52|cit52","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"7303","key":"10.1002\/14651858.CD005088.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD005088.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/000348940211101014","article-title":"Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey","volume":"111","author":"Kuurila","year":"2002","journal-title":"The Annals of Otology, Rhinology, and Laryngology"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"American Journal of Human Genetics"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","article-title":"Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta","volume":"33","author":"Mart\u00ednez-Glez","year":"2012","journal-title":"Human Mutation"},{"key":"10.1002\/14651858.CD005088.pub3-BIB58|cit58","unstructured":"Osteogenesis Imperfecta Foundation Facts about Osteogenesis Imperfecta www.oif.org"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajmg.1320590218","article-title":"Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta","volume":"59","author":"Orioli","year":"1995","journal-title":"American Journal of Medical Genetics"},{"issue":"4","key":"10.1002\/14651858.CD005088.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajhg.2013.02.009","article-title":"WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta","volume":"92","author":"Pyott","year":"2013","journal-title":"American Journal of Human Genetics"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A Mutation in the 5'-UTR of IFITM5 Creates an In-Frame Start Codon and Causes Autosomal-Dominant Osteogenesis Imperfecta Type V with Hyperplastic Callus","volume":"91","author":"Semler","year":"2012","journal-title":"American Journal of Human Genetics"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD005088.pub3-BIB64|cit64","series-title":"International committee for constitutional disorders of the skeleton","article-title":"Osteogenesis Imperfecta","author":"Sillence","year":"2012"},{"key":"10.1002\/14651858.CD005088.pub3-BIB65|cit65","unstructured":"Steiner RD Adsit J Basel D Gene Reviews; COL1A1\/2 -Related Osteogenesis Imperfecta http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1295\/"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/adc.2006.093997","article-title":"Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis","volume":"91","author":"Thornton","year":"2006","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD005088.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"Dijk","year":"2009","journal-title":"American Journal of Human Genetics"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD005088.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005088.pub3-BIB70|cit70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub2","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005088.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005088.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:44:45Z","timestamp":1628531085000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005088.pub3"}},"subtitle":[],"editor":[{"given":"Donald","family":"Basel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005088.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD005088.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2014,7,23]]}}}